Better Health Through Research image
 Better Health Through Research image
      

Search Center...



SEARCH PARAMETERS
Search:
Journal: Author:
Years: through Show:  Display: 
 

  Page 1 of 100  
Search Results for : Psoriatic Arthritis
Merck Online Lab
Diagnosis Therapy Rehabilitation Imaging Clinical Laboratory
Successful use of etanercept in acquired angioedema in a patient with psoriatic arthritis.
Author(s): Rottem, M; Mader, R
Journal: J Rheumatol 2010 Apr 7; Vol. 37, Issue 1; Page(s) 209
[Medline ID - 20040647]

ABSTRACT NOT AVAILABLE

Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritis.
Author(s): Driessen, RJ; de Jong, EM; Salemink, GW; B; ürer, JH; van de Kerkhof, PC; van den Hoogen, FH
Journal: Rheumatology (Oxford) 2009 Dec 31; Vol. 49, Issue 3; Page(s) 588-91
[Medline ID - 20040525]

OBJECTIVES: To get the approval for reimbursement of biological therapies for PsA, patients need to fulfil specific criteria in many countries. The aim of this study was to evaluate the 4-year Dutch reimbursement application data, including the diagnostic, disease activity and response criteria that were applied for treatment of PsA with biologics. METHODS: All initial and follow-up applications for approval of treatment with biologics were included for investigation. Data were analysed descriptively with regard to application characteristics, patient characteristics and response to therapy. RESULTS: In the period studied, 3723 application forms of 1991 patients were received. This concerned 2118 initial treatment applications and 1605 follow-up applications. Of all initial treatment applications, 2003 (94.6%) were approved. The major part of all applications concerned requests for etanercept (59.1%), followed by adalimumab (38.2%). Patients were suffering from polyarthritis in most cases (63.1%). MTX was used by nearly all patients, but only 55.8% had used the required dosage of 25 mg/week. Approximately 79.4% of all patients met the response criteria after 3 months of treatment. The mean number of affected joints declined from 7.7 at first application to 1.4 at follow-up. The initial visual analogue scale (VAS) score indicated by patients decreased from 71.2 to 24.1 at follow-up. The VAS score indicated by physicians decreased from 66.0 to 18.4. CONCLUSIONS: Biologics are expensive, but highly effective in the treatment of PsA. Careful compilation of treatment and reimbursement criteria is important for patients as well as for physicians and health insurance companies.

The protein tyrosine phosphatase, non-receptor type 22 R620W polymorphism does not confer susceptibility to psoriasis in the genetic homogeneous population of Crete.
Author(s): Zervou, MI; Castro-Giner, F; Sidiropoulos, P; Boumpas, DT; Tosca, AD; Krueger-Krasagakis, S
Journal: Genet Test Mol Biomarkers 2010 May 26; Vol. 14, Issue 1; Page(s) 107-11
[Medline ID - 20039785]

Recent whole-genome and candidate-gene association studies in patients with psoriasis (PS) have identified a number of single-nucleotide polymorphisms (SNPs) that predispose to disease with moderate risk. Predisposition to PS is known to be affected by genetic variation in human leukocyte antigen-C as well as other non-human leukocyte antigen genes. We recently reported for the first time as a PS-associated SNP the signal transducer and activator of transcription-4 (STAT4) rs7574865 polymorphism, which is also associated with several autoimmune diseases. The aim of this study was to assess whether the functional R620W polymorphism of protein tyrosine phosphatase, non-receptor type 22 (PTPN22) gene encoding the lymphoid-specific tyrosine phosphatase, which is known to be associated with various autoimmune diseases, also confers increased risk for PS in the genetic homogeneous population of Crete. A case-control study was performed with 173 PS patients consecutively recruited and 348 healthy controls, all of them from the island of Crete. We found that the mutated T allele of the PTPN22 1858T SNP was more common in control individuals than in patients with PS (odds ratio = 0.39, 95% confidence interval = 0.11-1.04, p = 0.09). No considerable difference was observed in terms of sex, age of onset, or clinical presentation of psoriatic arthritis. Our results provide evidence that the PTPN22 1858T allele is not a susceptibility factor for PS in the Cretan population.

Functional autoantibodies against serpin E2 in rheumatoid arthritis.
Author(s): Maciejewska-Rodrigues, H; Al-Shamisi, M; Hemmatazad, H; Ospelt, C; Bouton, MC; J; äger, D; Cope, AP; Charles, P; Plant, D; Distler, JH; Gay, RE; Michel, BA; Knuth, A; Neidhart, M; Gay, S; J; üngel, A
Journal: Arthritis Rheum 2010 Mar 12; Vol. 62, Issue 1; Page(s) 93-104
[Medline ID - 20039430]

OBJECTIVE: To search for novel autoantibodies in patients with rheumatoid arthritis (RA) in an effort to better understand the processes of joint destruction in this disease. METHODS: Using a modified SEREX technique and complementary DNA derived from RA synovium, serpin E2 was identified as a novel autoantigen and was analyzed by immunohistochemistry. Levels of anti-serpin E2 autoantibodies in serum and synovial fluid from patients with RA, osteoarthritis (OA), psoriatic arthritis, and ankylosing spondylitis, and/or from healthy individuals were assessed by enzyme-linked immunosorbent assay. Since serpin E2 is an inhibitor of serine proteases, we studied the inhibitory activity of serpin E2 toward its target, urokinase plasminogen activator (uPA), in vitro in the presence of isolated anti-serpin E2 autoantibodies and in vivo using the uPA activity assay. RESULTS: We identified autoantibodies against serpin E2 by the SEREX technique. Serpin E2 was overexpressed in RA synovial tissues as compared with OA synovial tissues. Significantly higher levels of anti-serpin E2 autoantibodies were present in samples of synovial fluid (28%) and serum (22%) from RA patients as compared with OA patients (0 and 6%, respectively) or with healthy individuals (6% of sera). Most importantly, anti-serpin E2 autoantibodies isolated from RA sera reversed the inhibitory activity of serpin E2 by 70%. Furthermore, the levels of anti-serpin E2 autoantibodies correlated with the uPA activity i n vivo. CONCLUSION: This study characterizes a functional property of a novel autoantibody in RA. Since anti-serpin E2 autoantibodies interfere with the inhibitory activity of serpin E2 toward serine proteases, they might facilitate the joint destruction in RA.

Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.
Author(s): Daoussis, D; Liossis, SN; Solomou, EE; Tsanaktsi, A; Bounia, K; Karampetsou, M; Yiannopoulos, G; Andonopoulos, AP
Journal: Arthritis Rheum 2010 Mar 12; Vol. 62, Issue 1; Page(s) 150-8
[Medline ID - 20039407]

OBJECTIVE: Dkk-1 is an inhibitory molecule that regulates the Wnt pathway, which controls osteoblastogenesis. This study was undertaken to explore the potential role of Dkk-1 in ankylosing spondylitis (AS), a prototypical bone-forming disease. METHODS: Serum Dkk-1 levels were measured in 45 patients with AS, 45 patients with rheumatoid arthritis (RA), 15 patients with psoriatic arthritis (PsA), and 50 healthy subjects by sandwich enzyme-linked immunosorbent assay (ELISA). A functional ELISA was used to assess the binding of Dkk-1 to its receptor (low-density lipoprotein receptor-related protein 6). Furthermore, we studied the effect of sera from patients with AS and healthy subjects on the activity of the Wnt pathway in the Jurkat T cell model, with and without a neutralizing a nti-Dkk-1 monoclonal antibody, by Western immunoblotting. RESULTS: Serum Dkk-1 levels were significantly increased in patients with AS (mean +/- SEM 2,730 +/- 135.1 pg/ml) as compared with normal subjects (P = 0.040), patients with RA (P = 0.020), and patients with PsA (P = 0.049). Patients with AS receiving anti-tumor necrosis factor alpha (anti-TNFalpha) treatment had significantly higher serum Dkk-1 levels than patients with AS not receiving such treatment (P = 0.007). Patients with AS studied serially prior to and following anti-TNFalpha administration exhibited a significant increase in serum Dkk-1 levels (P = 0.020), in contrast to patients with RA, who exhibited a dramatic decrease (P < 0.001). Jurkat cells treated with serum from AS patients exhibited increased Wnt signaling compared with cells treated with control serum. In that system, Dkk-1 blockade significantly enhanced Wnt signaling in control serum-treated, but not AS serum-treated, Jurkat T cells. CONCLUSION: Our findings indicate that in patients with AS, circulating bone formation-promoting factors functionally prevail. This can be at least partially attributed to decreased Dkk-1-mediated inhibition.

Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study.
Author(s): Angel, K; Provan, SA; Gulseth, HL; Mowinckel, P; Kvien, TK; Atar, D
Journal: Hypertension 2010 Feb 23; Vol. 55, Issue 2; Page(s) 333-8
[Medline ID - 20038753]

The chronic inflammatory state of rheumatoid arthritis and other inflammatory arthropathies, such as ankylosing spondylitis and psoriatic arthritis, contributes to the accelerated atherosclerosis associated with these conditions. This study evaluates the effect of treatment with tumor necrosis factor (TNF)-alpha antagonists on arterial stiffness in patients with inflammatory arthropathies. A total of 60 patients with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis and clinical indication for anti-TNF-alpha therapy were included. Thirty-five patients started with anti-TNF-alpha therapy and were compared with a nontreatment group of 25 patients. Aortic stiffness (aortic pulse wave velocity), augmentation index, and disease activity were assessed at bas eline and after 3 months. Aortic pulse wave velocity (mean+/-SD) was reduced in the treatment group but not in the control group (-0.50+/-0.78 m/s versus 0.05+/-0.54 m/s, respectively; P=0.002). Concomitantly, C-reactive protein and the disease activity score were reduced in the treatment group (-9.3+/-20.2 mg/L [P < 0.001] and -0.74+/-0.91 [P=0.004]). Augmentation index remained unchanged in both groups (0.1+/-7.1% versus -1.0+/-5.8%, respectively; P=0.53). In a multivariate linear regression model, only treatment with TNF-alpha antagonist and change in mean arterial pressure predicted alterations in aortic pulse wave velocity. In summary, anti-TNF-alpha therapy improved aortic stiffness in patients with inflammatory arthropathies. These findings support the idea that anti-inflammatory treatment has a favorable effect on cardiovascular risk in patients with inflammatory arthropathies.

Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis.
Author(s): Chandran, V; Raychaudhuri, SP
Journal: J Autoimmun 2010 Sep 8; Vol. 34, Issue 3; Page(s) J314-21
[Medline ID - 20034760]

Psoriasis and Psoriatic Arthritis (PsA) are chronic inflammatory diseases that have a major impact on health. The prevalence and incidence estimates of these two closely related diseases show ethnic and geographic variations, being generally more common in the colder north than in the tropics. In Europe the prevalence of psoriasis varies anywhere from 0.6 to 6.5%. In the USA, the estimated prevalence of diagnosed psoriasis is 3.15%. The prevalence in Africa varies depending on geographic location, being lowest in West Africa. Psoriasis is less prevalent in China and Japan than in Europe, and is entirely absent in natives of the Andean region of South America. There are fewer reports on the incidence of psoriasis, but a recent study from Rochester, USA showed an increasing trend over the last 2 decades. The prevalence of PsA also shows similar variation, being highest in people of European descent and lowest in the Japanese. Although, study methodology and case definition may explain some of the variations, genetic and environmental factors are important. Genetic epidemiologic studies have shown that both diseases have a strong genetic component. The strongest association is with HLA-Cw*06. Associations with a number of genes including IL12B and IL23R have recently been confirmed. Environmental risk factors including streptococcal pharyngitis, stressful life events, low humidity, drugs, HIV infection, trauma, smoking and obesity have been associated with psoriasis and PsA. Here we have reviewed the current literature on the epidemiology and genetics of psoriasis and PsA.

Varicella zoster virus infection in patients taking the TNF-alpha inhibitor, etanercept: coincidence or causal?
Author(s): Izumi, A
Journal: Hawaii Med J 2010 Feb 3; Vol. 68, Issue 11; Page(s) 277-8
[Medline ID - 20034255]

Ninety percent of varicella infections are seen in children under the age of ten and usually follow a benign clinical course with complete resolution of symptoms in one to three weeks. Herpes zoster an acute vesicular eruption due to the varicella-zoster virus (VZV), occurs mostly in adults. Biologic agents include tumor necrosis factor alpha (TNF-alpha) inhibitors that have significantly impacted the treatment of autoimmune and inflammatory conditions. Therapy with TNF-alpha inhibitors poses a potential risk of serious infections secondary to their immunomodulating properties; however multiple studies have demonstrated acceptable safety and tolerability profiles. A case of documented VZV infection (varicella) in an adult receiving the TNF-alpha inhibitor etanercept is described here.

Vitamin D level: is it related to disease activity in inflammatory joint disease?
Author(s): Braun-Moscovici, Y; Toledano, K; Markovits, D; Rozin, A; Nahir, AM; Balbir-Gurman, A
Journal: Rheumatol Int 2009 Dec 25
[Medline ID - 20033415]

The objectives of this study are to assess the vitamin D status in patients (pts) with inflammatory joint diseases (IJD), and its correlation with disease activity. 121 consecutive pts (85 rheumatoid arthritis (RA), 22 psoriatic arthritis (PSA), 14 ankylosing spondylitis (AS)) underwent clinical and laboratory evaluation which included kidney and liver function tests, serum calcium and phosphor levels, 25(OH)D and parathyroid hormone (PTH). Disease activity was assessed by DAS 28 in RA and PSA pts and by BASDAI in AS pts, sedimentation rate (ESR) and CRP. According to activity indexes, pts were divided into subgroups with low (DAS28 < 3.2 and BASDAI < 4), and moderate-to-high disease activity (DAS28 > 3.2 and BASDAI > 4). Associations between serum levels of 25(OH)D and age, gender, ethnicity, type and disease duration, treatment, (anti-tumor necrosis factoralpha (TNFalpha) agents or DMARDs), seasonal variations, and disease activity were assessed. Vitamin D deficiency was found in 51 pts (42.1%). The incidence was higher among Arab pts (76.7%) compared to Jews (23%). The difference of 25(OH)D levels between Arabs (mean 9.4 +/- 4.2 ng/ml) and Jews (mean 17.8 +/- 8.4 ng/ml) was statistically significant (p < 0.0001). We did not find correlation between vitamin D levels and the other evaluated factors. A surprisingly high incidence of vitamin D deficiency was found in IJD patients in a sunny Mediterranean country. This finding justifies the inclusion of vitamin D in the routine lab work-up of pts with IJD. The only statistical significant correlation was found between vitamin D level and ethnic origin. Further studies are needed to look for genetic polymorphism of vitamin D receptors.

Sacroiliac joint pathologies in low back pain.
Author(s): Gupta, AD
Journal: J Back Musculoskelet Rehabil 2010 Apr 7; Vol. 22, Issue 2; Page(s) 91-7
[Medline ID - 20023336]

OBJECTIVE: The study describes the clinical spectrum of patients with low back pain due to sacroiliac joint (SIJ) involvement with the proposition of a diagnostic scheme. METHODS: In this retrospective review, 61 patients with SIJ pain (unilateral or bilateral) greater than six weeks duration were evaluated by pain history, clinical examination including SIJ provocative tests, laboratory investigations and skeletal imaging. RESULTS: Fifty two patients (M: F, 31:21) were diagnosed to have specific SIJ pathologies amongst 61 patients presenting between 2002 to 2004. Forty patients (65%) were diagnosed with rheumatic conditions - ankylosing spondylitis (AS) - 21, undifferentiated spondyloarthropathy (UspA) - 11, psoriatic arthropathy (PS) - 5, reactive arthropathy (ReA) - 1 and juvenile spondyloarthropathy (JS)-2. Non rheumatic conditions were involved in 12 patients (20%) - osteitis condensus ilii (OCI) - 4, osteomalacia - 2, tuberculosis - 2, pyogenic arthritis - 1, pregnancy related sacroiliac joint pain - 2 and malignancy in 1 patient. The diagnosis could not be confirmed in 9 patients (15%). CONCLUSIONS: Medical history, clinical examination including SIJ tests, plain radiography and laboratory investigations were helpful in diagnosing SIJ pathology in 39% cases (n = 24), 46% (n = 28) needed CT or MRI. A diagnostic scheme of dividing the SIJ pathologies into rheumatic and non-rheumatic conditions was helpful in evaluating patients with suspected SIJ pathologies.
  Page 1 of 100  




 



Resource Center

 - Merck Manual

 - Lab Test On-Line

 - MeSH Search



Clinical Conditions

 - A/C Degeneration

 - Adolescent Low Back

 - Ankle Sprain

 - Ankylosing Spondylitis

 - Arthritides

 - Brachial Plexus Neuritis

 - Carpal Tunnel Syndrome

 - Headache/Cephalgia

 - Cervical Disc Degen

 - Cervical Sprain

 - Cervical Strain

 - Cervical Osteoarthritis

 - Cervical Radiculopathy

 - Cervical Spine Instability

 - Cervical Spondylosis

 - Cervical Torticollis

 - Chronic Low Back Pain

 - Chronic Pain

 - Disc Displacement

 - Facet Arthropathy

 - Facet Capsulitis

 - Failed Back

 - Fibromyalgia

 - Frozen Shoulder

 - Knee Sprain

 - Lateral Epicondylitis

 - Low Back Pain

 - Lumbar Disc Degen

 - Lumbar Stenosis

 - Metatarsalgia

 - Psoriatic Arthritis

 - Reactive Arthritis

 - Rheumatoid Arthritis

 - Rotator Cuff Syndrome

 - SI Dysfunction

 - Sciatica

 - Scoliosis

 - Shoulder Bursitis

 - Spondylolisthesis

 - Stroke

 - Tarsal Tunnel Syndrome

 - TMD

 - Tendinopathy

 - Thoracic Outlet Syn

 - Ulnar Nerve Entrapment

 - Whiplash Injuries

 - Wrist Sprain



Resources

 - Chiropractic Organizations

 - State Associations

 - Schools & Institutions

 - NIH Grants Feed

 - HRSA Grants Feed

 - Evidence-Based Resource

 - Journal Links


Bookmark and Share

|  Home  |


 Copyright © 2007 - | DCConsult.com | All Rights Reserved.


the primary url for this site ( "DCConsult" ) is http://DCConsult.com




Category : Topics




Support for DCConsult provided by :